14062 results about "Pyridine" patented technology

A method and apparatus for sequestering entrained or volatile catalyst species in a carbonylation process includes contacting the product stream with a vinyl pyridine or a vinyl pyrrolidone resin bed which is operative to sequester entrained or volatile catalytic species. The invention is particularly useful in connection with the iridium catalyzed carbonylation of methanol wherein the loss of entrained or volatile catalyst species depletes the catalytic content of the reactor. The resin may be digested in order to recover the catalytic metals.

An OLED device comprising a cathode, an anode, and having located therebetween a light emitting layer containing an emitting compound having formula (I): (piq)b M ppy   (I) wherein piq is a phenylisoquinoline group and ppy is a phenylpyridine group bearing at least one further substituent on the pyridine ring, wherein M is Ir, Rh, Pt, or Pd and b is 2 in the case of Ir and Rh and 1 in the case of Pt and Pd.

The present invention generally comprises a silicon dioxide atomic layer deposition method. By providing pyridine as a catalyst, water may be utilized as the oxidization source while depositing at a low temperature. Prior to exposing the substrate to the water, the substrate may be exposed to a pyridine soak process. Additionally, the water may be co-flowed to the chamber with the pyridine through separate conduits to reduce interaction prior to entering the chamber. Alternatively, the pyridine may be co-flowed with a silicon precursor that does not react with pyridine.

A Ge—Sb—Te film forming method includes a Sb source material introducing process, a first purging process, a Te source material introducing process, a second purging process, a Ge source material introducing process, a third purging process. An additive gas containing at least one of ammonia, methylamine, dimethylamine, hydrazine, monomethylhydrazine, dimethylhydrazine and pyridine is introduced in at least one of the Sb, Te and Ge source material introducing processes and the first to third purging processes.

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases ("PKs"). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

The present invention pertains to a method for manufacturing alkylate oil using a composite ionic liquid as catalyst. A mixture of isobutane and C4 olefins is used as the raw material, and a composite ionic liquid is used as catalyst to carry out an alkylation reaction. The alkane / olefin ratio in the raw material is higher than 1:1. In the composition of the aforementioned composite ionic liquid catalyst, the cations come from a hydrohalide of an alkyl-containing amine or pyridine, while the anions are composite coordinate anions coming from two or more metal compounds. One of the metal compounds is an aluminum compound, while other metal compounds are compounds of Group IB and Group IIB elements of the Periodic Table and the transition metals. The present invention also provides a design of static mixer reaction apparatus that can realize the aforementioned manufacturing method. The method of the present invention increases the selectivity of the alkylation reaction to give the alkylation product a relatively high octane number and further increase the product yield. Also, the manufacturing operation is simplified, and the cost can be reduced. This method is an environmentally friendly method that will not pollute the environment.

The present invention pertains to a method for manufacturing alkylate oil using a composite ionic liquid as catalyst. A mixture of isobutane and C4 olefins is used as the raw material, and a composite ionic liquid is used as catalyst to carry out an alkylation reaction. The alkane / olefin ratio in the raw material is higher than 1:1. In the composition of the aforementioned composite ionic liquid catalyst, the cations come from a hydrohalide of an alkyl-containing amine or pyridine, while the anions are composite coordinate anions coming from two or more metal compounds. One of the metal compounds is an aluminum compound, while other metal compounds are compounds of Group IB and Group IIB elements of the Periodic Table and the transition metals. The present invention also provides a design of static mixer reaction apparatus that can realize the aforementioned manufacturing method. The method of the present invention increases the selectivity of the alkylation reaction to give the alkylation product a relatively high octane number and further increase the product yield. Also, the manufacturing operation is simplified, and the cost can be reduced. This method is an environmentally friendly method that will not pollute the environment.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4)

The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

Provided are compounds represented by: X is O, S or NR6, R1 is H or (CH2)mR5, R2, R2', R3 and R3' are independently NO2, N3 or (CH2)mR5, OH R4 is H, OR6, SR6, NR6R6a, CN, C(O)OR6, C(O)NR6R6a, R6, OR7 or (CH2)nR7, R5 is H, halo, OR6, SR6, NR6R6a, CN, C(O)OR6, C(O)NR6R6a, R6, OR7 or (CH2)mR7, R6 and R6a are individually H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl or substituted aryl, R7 is: R8 is H, F, SR9 or OR9, R9 is H, alkyl, alkenyl, alkynyl, aryl or hydroxyprotecting group, Y is H, CH3 or (CH2)mR5, Z is O or S W is CH2, CF2, CHF or O, m is 0-4, B is adenine, guanine, cytosine, uracil, thymine, modified purines and pyrimidines substituted pyridines, five membered heterocycles substituted by at least one of amines, substituted amines, amides, substituted amides, esters, halogens, alkyls, ethers; and pharmaceutically acceptable salts thereof and prodrugs thereof. These ring systems may be substituted.

The invention discloses a catalyst modification method for preparing methyl acetate by carbonylating dimethyl ether. The method is applied to the reaction process in which the dimethyl ether reacts with the carbon monoxide to high selectively form methyl acetate in the presence of an acid molecular sieve catalyst, particularly a mordenite molecular sieve. Pyridine organic amines are utilized to modify the mordenite molecular sieve and modify a channel structure and the acidity of the molecular sieve, thereby effectively inhibiting carbon deposition and greatly improving the stability of catalysts. The use of the catalysts by the method can catalyze the carbonylation of dimethyl ether to obtain methyl acetate under mild conditions. The conversion rate of dimethyl ether is between 10 and 60percent, the selectivity of the methyl acetate is over 99 percent, and the activity of the catalysts is kept steady after the reaction is performed for 48 hours.

An herbicidal composition containing (a) a pyridine or pyrimidine carboxylic acid component and (b) a second cereal or rice herbicide component provides synergistic control of selected weeds.

Antimicrobial compositions and methods are disclosed. The antimicrobial compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. In one aspect the invention relates a UV curable antimicrobial coating comprising a UV curable composition comprising an oligomer, a momoner, and a photoinitiator which are together capable of forming a UV curable polymer composition. The compositions include rheology modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include cetyl pyridium chloride, cetrimide, alexidine, chlorexidine diacetate, benzalkonium chloride, and o-phthalaldehyde.

A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen, or C1-6alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl, or heteroarylC1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and R3 represents hydrogen or C1-3alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

The present invention relates to a process of providing the 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in substantially free form (Compound 1).

The present invention relates to compounds having the formula I: which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Disclosed are topical compositions for the treatment of microbial infections on the skin or scalp which include a polyvalent metal salt of pyrithione and include a metal ion source. Also disclosed are methods for treating microbial infections of the skin or scalp using such compositions.

A catalyst system comprising:(a) one or more bisarylimino pyridine iron or cobalt catalysts;(b) a first co-catalyst compound which is selected from aluminium alkyls, aluminoxanes, and mixtures thereof; and(c) a second co-catalyst compound which comprises one or more compounds of the formula ZnR′2 wherein each R′, which may be the same or different, is selected from hydrogen, optionally substituted C1–C20 hydrocarbyl, phenyl, Cl, Br, I, SR″, NR″2, OH, OR″, CN, NC wherein R″, which within the same molecule may the same or different, is C1–C20 hydrocarbyl.

The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I):and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.

The invention provides nitrogen mixed grapheme hydrogel of which the water content is 90 to 99.5 percent, the electric conductivity is 10-3-100 S / m, and the molar ratio of N and C is 1 to 25 percent. The invention further provides nitrogen mixed aerogel of which the molar ratio of N and C is 2 to 20 percent, the molar ratio of C and O is 15 to 5, nitrogen atoms existing in the form of amidogen nitrogen accounts for 40 to 70 percent, pyridine type nitrogen accounts for 10 to 40 percent, graphite type nitrogen accounts for 10 to 30 percent, the specific area is 300 to 1500 m<2> / g, the apertures which are micropore account for 10 to 20 percent, the apertures which are mesoporous 20 to 50 percent, the apertures which are macropore 30 to 70 percent, the apparent density is 0.01 to 0.2 g / cm<3>, the pore volume is 5 to 20 cm<3> / g, and the electric conductivity is 1 to 1000 S / m. The nitrogen mixed grapheme hydrogel or aerogel and preparation method thereof provided by the invention has the characteristics that the operation is simple, the equipment requirement is low, the production efficiency is high, the scale-up of the technology is easy, the nitrogen mixed content is controllable and the compounding with other functional substances is simple.

Novel iron and cobalt complexes of certain novel tricyclic ligands containing a “pyridine” ring and substituted with two imino groups are polymerization and / or oligomerization catalysts for olefins, especially ethylene. Depending on the exact structure of the ligand, and polymerization process conditions, products ranging from α-olefins to high polymers may be produced. The polymers, especially polyethylenes, are useful for films and as molding resins.